Antibiotic therapy for community-acquired pneumonia: what’s new?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Community-acquired pneumonia (CAP) remains a common and potentially life-threatening disease. The availability of new antibiotics opens up opportunities for expanding empirical therapy for patients with CAP caused by drug-resistant pathogens. However, it is necessary to make sure that the new antibiotics are effective and well tolerated by patients, as well as that their use is advisable in terms of minimizing the risk of developing antibiotic resistance. The success of CAP treatment depends on the urgent use of antibiotics that are effective against probable pathogens; physicians should take into account the severity of the course of the disease and the prevailing regional characteristics of antibiotic resistance in the process of choosing the appropriate treatment tactics.

Full Text

Restricted Access

About the authors

Aleksandr I. Sinopalnikov

Russian Medical Academy of Continuous Professional Education

Email: aisyn@list.ru
Dr. Sci. (Med.), Professor, Head of the Department of Pulmonology Moscow, Russia

References

  1. The top 10 causes of death. Geneva: World Health Organization, 2013. URL: http://www.who.int/mediacentre/factsheets/fs310/en/index.html
  2. Murphy S.L., Xu J., Kochanek K.D. Deaths: preliminary data for 2010. Natl Vital Stat Rep. 2012;60:1-51.
  3. Ferreira-Coimbra J., Sarda C., Rello J. Burden of community-acquired pneumonia and unmet clinical needs. Adv Ther. 2020;37:1302-18. doi: 10.1007/s12325-020-01248-7.
  4. Wunderink R.G., Waterer G.W. Community-acquired pneumonia. N Engl J Med. 2014;370:543-51. doi: 10.1056/NEJMcp1214869.
  5. Внебольничная пневмония у взрослых. Клинические рекомендации (2021). Доступно на: https://cr.minzdrav.gov.ru
  6. Cilloniz C., Dominedo C., Garcia-Vidal C., Torres A. Community-acquired pneumonia as an emergency condition. Curr Opin Crit Care 2018;24:531-39. doi: 10.1097/MCC.0000000000000550.
  7. Kollef M.H., Betthauser K.D. New antibiotics for community-acquired pneumonia. Curr Opin Infect Dis. 2019;32:169-75. Doi: 10.1097/ QCO.0000000000000526.
  8. Liapikou A., Cilloniz C., Palomepue A., Torres T. Emerging antibiotics for community-acquired pneumonia. Expert Opin Emerg Drugs. 2019;24(4):221-31. doi: 10.1080/14728214.2019.1685494.
  9. Pereira J.M., Goncalves-Pereira J., Ribeiro O., et al. Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the iNFAUCi study J Crit Care 2018;43:183-89. Doi: 10.1016/j.
  10. Cilloniz C., Gabarrus A., Ferrer M., et al. Community-acquired pneumonia due to multidrug- and nonmultidrug-resistant Pseudomonas aeruginosa. Chest. 2016;150:415-25. Doi: 10.1016/j. chest.2016.03.042.
  11. Iannini P.B., Paladino J.A., Lavin B., et al. A case series of macrolide treatment failures in community acquired pneumonia. J Chemother. 2007;19:536-doi: 10.1179/joc.2007.19.5.536.
  12. Aguilar P.R., Balsara K., Itoh A., Kollef M.H. A noteworthy case of acute bronchitis. Ann Am Thorac Soc. 2016;13:285-87. Doi: 10.1513/ AnnalsATS.201508-518CC.
  13. Waterer G.W., Wunderink R.G., Jones C.B. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest. 2000;118:1839-40. Doi: 10.1378/ chest.118.6.1839-a.
  14. Brown E.D., Wright G.D. Antibacterial drug discovery in the resistance era. Nature. 2016;529:336-43. doi: 10.1038/nature17042.
  15. Lewis K. Platforms for antibiotic discovery Nat Rev Drug Discov. 2013;12:371-83. Doi: 10.1038/ nrd3975.
  16. Lewis K. Antibiotics: Recover the lost art of drug discovery. Nature. 2012;485:4390440. doi: 10.1038/485439a.
  17. Schatz A., Bugie E., Waksman S.A. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. ProcSoc Exp Biol Med. 1944;55:66-9. doi: 10.1097/01. blo.0000175887.98112.fe.
  18. Browne K., Chakraborty S., Chen R., et al. A new era of antibiotics: the clinical potential of antimicrobial peptides. Int J Mol Sci. 2020;21:7047. doi: 10.3390/ijms21197047.
  19. Lewis K. The science of antibiotic discovery Cell. 2020;181:29-45. Doi: 10.1016/j. cell.2020.02.056.
  20. Peyrani P., Mandell L., Torres A., Tillotson G.S. The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. Expert Rev Respir Med. 2019;13:139-52. doi: 10.1080/17476348.2019.1562339.
  21. Spellberg B., Srinivasan A., Chambers H. New societal approaches to empowering antibiotic stewardship. JAMA. 2016;315:1229-30. doi: 10.1001/jama.2016.1346.
  22. Cilloniz C., Ardanuy C., Vila J., Torres A. What in the clinical relevance of drug-resistant pneumococcus? Curr Opin Pulm Med. 2016;22:227-34. doi: 10.1097/MCP0000000000000262.
  23. The 10x'20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020. CID. 2010;50:1081-83. doi: 10.1086/652237.
  24. Iizawa Y., Nagai J., Ishikawa T., et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother. 2004;10:146-56. doi: 10.1007/s10156-004-0309-3.
  25. Sader H.S., Fritsche T.R., Kaniga K., et al. Аntimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005;49:3501-12. doi: 10.1128/AAC.49.8.3501-3512.2005.
  26. Ghuysen J.M. Molecular structures of penicillin-binding proteins and ß-lactamases. Trends Micribiol. 1994;2:372-80. doi: 10.1016/0966-842x(94)90614-9.
  27. Kosowska-Shick K., McGhee P., Appelbaum P Affinity of ceftaroline and other ß-lactams for penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010;54:1670-77. doi: 10.1128/AAC.00019-10.
  28. Sader H.S., Fritsche T.R., Jones R.N. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52:1 153-55. doi: 10.1128/AAC.01351-07.
  29. Saravolatz L., Pawlak J., Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistanT., vancomycin-intermediate, vancomycin-resistanT., and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010;54:3027-30. doi: 10.1128/AAC.01516-09.
  30. Jacqueline C., Amador G., Batard E., et al. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. J. Antimicrob. Chemother. 2011;6:863-66. doi: 10.1093/jac/dkr019.
  31. Fenoll A., Aguilar L., Robledo O., et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother. 2008;52:4209-10. doi: 10.1128/AAC.00712-08.
  32. Patel S.N., Pillai D.R., Pong-Porter S., et al. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother. 2009;64:659-60. doi: 10.1093/jac/ dkp231.
  33. File T.M., Low D.E., Eckburg P.B., et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of caftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl.):iii19-32. doi: 10.1093/jac/ dkr096.
  34. Low D.E., File T.M., Eckburg P.B., et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of caftaroline fosamil versus ceftriaxone in communityacquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl.):iii33-44. doi: 10.1093/jac/ dkr097.
  35. Shorr A.F., Kollef M., Eckburg P.B., et al. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials. Diagn Microbiol Infect Dis. 2013;75:298-303. doi: 10.1016/j. diagmicrobio.2012.12.002.
  36. Ramirez J.A., Srinath L., Ahkee S., et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155:1273- 76.
  37. Ramirez J.A., Vargas S., Ritter G.W., et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159:2449-54. doi: 10.1001/ archinte.159.20.2449.
  38. Carreno J.J., Lodise T.P. Ceftaroline fosamil for the treatment of community-acquired pneumonia: from FOCUS to CAPTURE. Infect Dis. Ther. 2014;3:123-32.
  39. Bassetti M., Russo A., Cilloniz C., et al. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. Int J Antimicrob Agents. 2020;55:105921. doi: 10.1016/j.ijantimicag.2020.105921.
  40. Metlay J.P., Waterer G.W., Long A.C., et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(iss 7):e45-67. doi: 10.1164/ rccm.201908-1581ST.
  41. Duraes F., Sousa E. Omadacycline: A Newly approved antibacterial from the class of tetracyclines. Pharmaceuticals (Basel). 2019;12(2):63. doi: 10.3390/ph12020063.
  42. Noel G.J., Draper M.P., Hait H., et al. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012;56:5650-4. doi: 10.1128/AAC.00948-12.
  43. Gotfried M.H., Horn K., Garrity-Ryan L., et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother. 2017;61:e01135-17. doi: 10.1128/AAC.01135-17.
  44. Villano S., Steenbergen J., Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11:1421-34. doi: 10.2217/fmb-2016-0100.
  45. URL: https://www.clinicaltrials.gov/ct2/show/results/NCT02531438?term=omadacycline&ra nk=4
  46. Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia". www.globenewswire.com. April 3, 2017. Retrieved.
  47. URL:https://www.drugs.com/history/nuzyra.html
  48. Llano-Sotelo B., Dunkle J., Klepacki D., et al. Binding and action of CEM-101, a new Accepted Manuscript fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob. Agents Chemother. 2010;54:4961970. doi: 10.1128/AAC.00860- 10.
  49. Zhanel G.G., Hartel E., Adam H., et al. Solithromycin: a novel fluoroketolide for the treatment of community-acquired bacterial pneumonia. Drugs. 2016;76:1737-57. doi: 10.1007/s40265-016-0667-z.
  50. McGhee P., Clark C., Kosowska-Shick K.M., et al. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother. 2010;54:230-8. doi: 10.1128/AAC.01123-09.
  51. Jamieson B.D., Ciric S., Fernandes P. Safety and pharmacokinetics of solithromycin in subjects with hepatic impairment. Antimicrob Agents Chemother. 2015;59:4379-86. doi: 10.1128/ AAC.04652-14.
  52. Rodvold K.A., Gotfried M.H., Still J.G., et al. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother. 2012;56:5076-81. doi: 10.1128/AAC.00766-12.
  53. Oldach D., Clark K., Schranz J., et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother. 2013;57:2526-34. doi: 10.1128/AAC.00197- 13.
  54. File T.M., Rewerska B., Tanaseanu C.M., et al. SOLITAIRE-IV: A randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect.Dis. 2016;63:1007-16. doi: 10.1093/cid/ ciw490.
  55. Fernandes P., Martens E., Bertrand D., Pereira D. The solithromycin journey -it is all in the chemistry. Bioorg Med Chem. 2016;24:6420-8. doi: 10.1016/j.bmc.2016.08.035.
  56. FDA Briefing document Soiithromycin Oral Capsule and Injection Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). URL: https://www.fda.gov.2016
  57. Guo B., Wu X., Zhang Y., et al. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fiuorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Invest. 2012;32:475-86. doi: 10.2165/11632780-000000000-00000.
  58. Liu Y., Zhang Y., Wu J., et al. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of communityacquired pneumonia. J Microbiol Immunol Infect. 2017;50:811-20. doi: 10.1016/j.jmii.2015.09.005.
  59. van Rensburg D.J., Perng R.P., Mitha I.H., et al. Efficacy and safety of nemonoxacin Accepted Manuscriptversus levofloxacin for community acquired pneumonia. Antimicrob Agents Chemother. 2010;54:4098-106. doi: 10.1128/ AAC.00295-10.
  60. Cheng S., Wu R., Hsu Z., et al. Efficacy and safety of oral nemonoxacin in treatment of community-acquired pneumonia: subgroup analysis results in Taiwanese patients in a randomized, double-blind, multi-center, phase III comparative study with levofloxacin. 2015. Available at: www.atsjournals.org/doi/abs/10.1164/ajrccmconference 2015.191.1_Meeting Abstracts.A4063.
  61. Marra A., Bortolon E., Molstad D., et al. Evaluation of delafloxacin in rat granuloma pouch infections caused by gram-negative pathogens. In program and Abstract of 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA: Abstract; 2011. A1-680.
  62. Remy J.M., Tow-Keogh C.A., McConnell T.S., et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother. 2012;67:2814-20. doi: 10.1093/jac/dks307.
  63. Pfaller M.A., Sader H.S., Rhomberg P.R., Flamm R.K. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017;61:e02609-16. doi: 10.1128/ AAC.02609-16.
  64. Sheikh J. Clinical microbiology review. Delafloxacin. NDA#208610, 208611. Melinta Therapeutics, Inc. Division of Anti-Infective Products. Center for Drug Evaluation and Research. US Food and Drug Administration; 2017.
  65. Thabit A.K., Crandon J.L., Nicolau D.P Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Int J Antimicrob Agents. 2016;48:535-41. doi: 10.1016/j.ijantimicag.2016.08.012.
  66. URL: https://www.ciinicaitriais.gov/ct2/resuits?cond=&term=NCT02679573&cntry=&state=&ciy=&dist=
  67. Kocsis B., Domokos J., Szabo D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofioxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016;15:34. doi: 10.1186/s12941-016-0150-4.
  68. Fernandes P., Martens E. Antibiotics in late clinical development. Biochem Pharmacol. 2017;133:152-63. doi: 10.1016/j.bcp.2016.09.025.
  69. Novak R. Are pleuromutilin antibiotics finally fit for human use? Ann NY Acad Sci. 2011;1241:71-81. doi: 10.1111/j.1749-6632.2011.06219.x.
  70. Zeitlinger M., Schwameis R., Burian A., et al. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother. 2016;71:1022-26. doi: 10.1093/ jac/dkv442.
  71. Sader H.S., Paukner S., Ivezic-Schoenfeld Z., et al. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother. 2012;67:1170-75. doi: 10.1093/jac/dks001.
  72. Paukner S., Geione S.P., Arends S.J.R., et al. Antibacterial activity of Lefamulin against pathogens most commonly causing community-acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016). Antimicrob Agents Chemother. 2019;63:e02161-18. doi: 10.1128/AAC.02161-18.
  73. Prince W.T., Ivezic-Schoenfeid Z., Leii C., et al. Phase II clinical study of BC-3781, a Accepted Manuscript pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2013;57:2087-94. doi: 10.1128/AAC.02106-12.
  74. File T.M., Goldberg L., Das A., et al. Efficacy and safety of IV-to-Orai Lefamuiin, a pieuromutiiin antibiotic, for treatment of community-acquired bacterial pneumonia: The Phase 3 LEAP 1 Trial. Clin Infect Dis. 2019;69:1856-67. doi: 10.1093/cid/ ciz090.
  75. Gasink L. Study to compare lefamulin to moxifloxacin for the treatment of adults with pneumonia (LEAP2). 2016. Available at: https: //clinicaltrials.gov/ct2/show/NCT02813694
  76. Eyal Z., Matzov D., Krupkin M., et al. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci Rep. 2016;6:39004.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies